Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT.
Burger PM, Bhatt DL, Dorresteijn JAN, Koudstaal S, Mosterd A, Martens FMAC, Steg PG, Visseren FLJ; REDUCE-IT Investigators. Burger PM, et al. Among authors: bhatt dl. Eur Heart J Cardiovasc Pharmacother. 2024 Oct 4;10(6):488-499. doi: 10.1093/ehjcvp/pvae030. Eur Heart J Cardiovasc Pharmacother. 2024. PMID: 38678009 Clinical Trial.
Comparison of change in lipoprotein(a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events in ODYSSEY OUTCOMES.
Szarek M, Reijnders E, Steg PG, Jukema JW, Schwertfeger M, Bhatt DL, Bittner VA, Diaz R, Fazio S, Garon G, Goodman SG, Harrington RA, White HD, Zeiher AM, Cobbaert C, Schwartz GG. Szarek M, et al. Among authors: bhatt dl. Eur J Prev Cardiol. 2024 Aug 9;31(10):e75-e78. doi: 10.1093/eurjpc/zwae110. Eur J Prev Cardiol. 2024. PMID: 38501249 Clinical Trial. No abstract available.
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.
Goodman SG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Harrington RA, Jukema JW, White HD, Zeiher AM, Manvelian G, Pordy R, Poulouin Y, Stipek W, Garon G, Schwartz GG; ODYSSEY OUTCOMES Investigators. Goodman SG, et al. Among authors: bhatt dl. Eur Heart J Cardiovasc Pharmacother. 2024 Jul 16;10(4):342-352. doi: 10.1093/ehjcvp/pvae025. Eur Heart J Cardiovasc Pharmacother. 2024. PMID: 38658193 Free PMC article. Review.
DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases.
Handelsman Y, Anderson JE, Bakris GL, Ballantyne CM, Bhatt DL, Bloomgarden ZT, Bozkurt B, Budoff MJ, Butler J, Cherney DZI, DeFronzo RA, Del Prato S, Eckel RH, Filippatos G, Fonarow GC, Fonseca VA, Garvey WT, Giorgino F, Grant PJ, Green JB, Greene SJ, Groop PH, Grunberger G, Jastreboff AM, Jellinger PS, Khunti K, Klein S, Kosiborod MN, Kushner P, Leiter LA, Lepor NE, Mantzoros CS, Mathieu C, Mende CW, Michos ED, Morales J, Plutzky J, Pratley RE, Ray KK, Rossing P, Sattar N, Schwarz PEH, Standl E, Steg PG, Tokgözoğlu L, Tuomilehto J, Umpierrez GE, Valensi P, Weir MR, Wilding J, Wright EE Jr. Handelsman Y, et al. Among authors: bhatt dl. Metabolism. 2024 Oct;159:155931. doi: 10.1016/j.metabol.2024.155931. Epub 2024 Jun 7. Metabolism. 2024. PMID: 38852020 Free article.
Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: a report from the ODYSSEY OUTCOMES study.
Bittner VA, Schwartz GG, Bhatt DL, Chua T, De Silva HA, Diaz R, Goodman SG, Harrington RA, Jukema JW, McGinniss J, Pordy R, Garon G, Scemama M, White HD, Steg PG, Szarek M; ODYSSEY OUTCOMES Investigators. Bittner VA, et al. Among authors: bhatt dl. J Clin Lipidol. 2024 Jul-Aug;18(4):e548-e561. doi: 10.1016/j.jacl.2024.04.122. Epub 2024 Apr 10. J Clin Lipidol. 2024. PMID: 38960812 Free article. Clinical Trial.
Origins and Previous Applications of Causal-Benefit Models.
Dorresteijn JAN, Hageman SHJ, Visseren FLJ, Bhatt DL. Dorresteijn JAN, et al. Among authors: bhatt dl. JACC Adv. 2024 Jul 29;3(9):101089. doi: 10.1016/j.jacadv.2024.101089. eCollection 2024 Sep. JACC Adv. 2024. PMID: 39165835 Free PMC article. No abstract available.
Effect of Four Hemoglobin Transfusion Threshold Strategies in Patients With Acute Myocardial Infarction and Anemia : A Target Trial Emulation Using MINT Trial Data.
Portela GT, Carson JL, Swanson SA, Alexander JH, Hébert PC, Goodman SG, Steg PG, Bertolet M, Strom JB, Fergusson DA, Simon T, White HD, Cooper HA, Abbott JD, Rao SV, Chaitman BR, Fordyce CB, Lopes RD, Daneault B, Brooks MM; MINT Investigators; MINT Investigators*. Portela GT, et al. Ann Intern Med. 2024 Oct 1. doi: 10.7326/M24-0571. Online ahead of print. Ann Intern Med. 2024. PMID: 39348705
Influenza Vaccine Immune Response in Patients With High-Risk Cardiovascular Disease: A Secondary Analysis of the INVESTED Randomized Clinical Trial.
Peikert A, Claggett BL, Udell JA, Joseph J, Hegde SM, Kim K, Mao L, Wang T, Havighurst TC, Farkouh ME, Bhatt DL, Tattersall MC, Cooper LS, Solomon SD, Vardeny O. Peikert A, et al. Among authors: bhatt dl. JAMA Cardiol. 2024 Jun 1;9(6):574-581. doi: 10.1001/jamacardio.2024.0468. JAMA Cardiol. 2024. PMID: 38583091 Free PMC article. Clinical Trial.
Smoking Habits Following Cancer Diagnosis and Heart Failure.
Lee HH, Jiang C, Bhatt DL, Kim HC, Lee H. Lee HH, et al. Among authors: bhatt dl. JAMA Netw Open. 2024 Oct 1;7(10):e2437867. doi: 10.1001/jamanetworkopen.2024.37867. JAMA Netw Open. 2024. PMID: 39374022 Free article.
2,175 results